Provider review
MyDrHank review: its weight-loss figures contradict the citation printed underneath them
In our September source check: MyDrHank's weight-loss page carries one of the better citations in this market: both trials named, with authors, journals, sample sizes, durations and doses, and an admission that the data covers approved drugs rather than the compounded ones it sells. Then look just above it. Four statistics sit there, and two contradict the footnote beneath them. The card marked tirzepatide reads 14.9%, which is semaglutide's result from the trial that footnote names. MyDrHank wrote the correct version too. It is in the same file, and this is not the page it put it on.
Partner link — we may earn a commission. How we’re paid
Visit MyDrHankOf MyDrHank’s 3 dated product claims documented below, 1 is consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $259 for 30 days (Compounded semaglutide injection, one month bought outright). A matching claim does not mean the compounded product was tested or FDA-approved.
In our September source check: Writes one of the better trial citations in this market. Then prints two figures above it that its own footnote contradicts.
Worth trusting if
- You read footnotes, because this one names both trials properly and admits what they do not cover
- You want a seller that says out loud that trial data covers approved drugs and not compounded ones
- You can pay a year up front, which is the only way to get the rate the page advertises
Be skeptical if
- You want the headline statistics to be the reliable ones, because here the small print is
- You want the pharmacy named rather than described as licensed
- You want to know which company you are buying from, because the terms name none
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at MyDrHank
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded tirzepatide injection — $349 for a single month; the advertised rate is a year paid up front at $240 a month.
- Compounded semaglutide injection — $259 for a single month; $178 a month on a year paid up front.
- Oral semaglutide tablet — $249 for a single month; $171 a month on a year paid up front — the one headline on the page that matches the price list behind it.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
3
Products with human evidence
For the advertised use, out of 3 products reviewed here. The evidence concerns the molecule, not MyDrHank's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from MyDrHank’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded tirzepatide injectionTirzepatide · Compounded (503A)No trial supports this claim
“14.9% Average weight loss (tirzepatide). On average, patients on GLP-1 treatment lose up to 14.9% of their body weight.”
Read on the MyDrHank site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, reporting a mean reduction of about 21% at the top dose. MyDrHank's own footnote cites this trial and this figure — the card above it does not.
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults on semaglutide 2.4 mg, reporting about 15%. Listed here because 14.9% is this trial's result, and it is the number MyDrHank prints under tirzepatide.
The figure is real and it belongs to the other drug. MyDrHank's footnote, on this same page, cites about 20.9% for tirzepatide from SURMOUNT-1 and about 15% for semaglutide from STEP 1 — and 14.9% is that semaglutide figure, printed on the card labeled tirzepatide. Worth being precise about the direction, because it is unusual: this understates tirzepatide rather than inflating it, so nobody is being oversold. The problem for a reader is simpler than exaggeration. Two numbers on one screen disagree about the same trial, which means the screen cannot settle what the drug does, and the more careful of the two is the one set in small type at the bottom.1,2
Compounded semaglutide injectionSemaglutide · Compounded (503A)No trial supports this claim
“8.3% Average weight loss (semaglutide).”
Read on the MyDrHank site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults titrated to semaglutide 2.4 mg weekly, reporting a mean reduction of about 15% against about 2% on placebo. This is the trial and the figure MyDrHank's own footnote cites for semaglutide.
The card carries footnote marker one, and footnote one says about 15%. The card says 8.3%. 8.3% matches no study the page cites, and what can be checked is that the citation attached to this number gives a different number for the same molecule. The site also carries a corrected version of this block that it does not display, and that version reads 15% here. So the company knows which figure belongs on this card; it simply is not the version a reader arriving from an affiliate link is shown.1
Oral semaglutide tabletSemaglutide · Compounded (503A)Claim matches the trials
“A GLP-1 receptor agonist in tablet form — reduces appetite and helps you feel full longer. Prescribed by a licensed provider and shipped from accredited U.S. pharmacies.”
Read on the MyDrHank site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Included because it is the semaglutide evidence MyDrHank cites. STEP 1 tested a weekly injection of 2.4 mg, not a compounded tablet, so it describes the molecule rather than this preparation.
Nothing here overstates anything. The description of how the molecule works is accurate and carries no percentage, which is the right way to sell a formulation that has no trial of its own. One thing a reader should hold on to: the evidence MyDrHank cites anywhere on this page comes from a weekly injection, and a compounded tablet is a different preparation by a different route. That gap is not unique to this seller and it is not closed by any figure on the page.1
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. The lander says medication ships from licensed U.S. pharmacies and the product copy says accredited U.S. pharmacies, and neither phrase is attached to a facility, an address or a license number. No clinician is named either — not a prescriber, not a medical director — beyond a promise that a U.S.-licensed physician reviews each case, with a stated turnaround of about a day. No operating company appears in the terms. That holds across the lander, the intake and the terms.
Read on the MyDrHank site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published, and no third-party certification is displayed. The strongest quality-related statement on the site is that pharmacies are licensed and accredited, with neither claim tied to a named facility anyone could check. Against that, footnote 1 does something better than most: it says the trial data covers FDA-approved formulations rather than the compounded versions MyDrHank dispenses. That sentence is an honest limit on the evidence, and it is the reason the mislabeled figures above it are worth flagging rather than shrugging at.
Read on the MyDrHank site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
MyDrHank publishes no list of states and makes no fifty-state claim, on the lander, in the intake or in the terms. What it does say is that its physicians are U.S.-licensed and the program runs entirely online with no office visits.
Read the full licensing claim
No operating entity, registered address or state of incorporation is published anywhere we looked. The site gives a support email and a telephone number and identifies itself only as the brand. It does set an eligibility floor, though you only meet it inside the questionnaire: a BMI over 25 if you have never taken a GLP-1, or over 20 if you have. Neither figure appears on the lander or in the terms.
Read on the MyDrHank site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Footnote 1 names both trials with authors, journals, years, sample sizes, durations and doses.
- It states that the trial data covers FDA-approved formulations, not the compounded versions it sells.
- It adds that individual results vary, rather than presenting a trial mean as an outcome.
Show 3 more
- The oral tablet is described by how it works, with no percentage attached to a formulation that has no trial.
- Its tirzepatide product copy elsewhere carries the correct 20.9% figure from SURMOUNT-1.
- A physician review is promised within about a day, and no membership or consultation fee sits on top.
- The card labeled tirzepatide reads 14.9%, which is semaglutide's result in the trial its own footnote names.
- The card labeled semaglutide reads 8.3%, while the footnote it cites gives about 15%.
- The sentence above both cards caps GLP-1 results at 14.9%, below the 20.9% the same footnote reports.
Show 4 more
- The site carries a corrected version of that whole block, and it is not the one this page shows.
- No pharmacy, clinician or operating company is named anywhere on the site.
- No certificate of analysis or third-party testing result is published.
- The site runs several GLP-1 landers that carry different figures, and which one you see depends on your link.
Verdict
The bottom line
In our September source check: Read the footnote and ignore the four big numbers above it. That is an odd thing to have to tell anyone. MyDrHank knows what STEP 1 and SURMOUNT-1 reported, cites them properly, and admits they tested drugs it does not sell. Then it shows a version of its own statistics that disagrees with all of that. Get the pharmacy named and the figures reconciled before you order.
Opens MyDrHank's website. A link is not a recommendation to take anything.
Before choosing a plan
The review below documents the September source check. We could not retrieve a usable current public product page during the October follow-up, so we are not presenting a new price or claiming the older screen still appears unchanged.
For a current quote, ask whether the total is for one supply period or a prepaid package, what renewal costs, and when cancellation must reach support. Also request the dispensing pharmacy and exact formulation. Those questions are independent of whether the promotional statistics have been corrected: an evidence citation does not answer what you must pay or who supplies your prescription.
We have not submitted an intake or tested the clinical service. The original source dates remain attached to the recorded findings.
Full analysis — 6 more sectionsThe contradiction, on one screen · Where 14.9% comes from · The correct version exists · Which direction the error runs · What the footnote gets right · What it won't tell you
The contradiction, on one screen
Four statistics sit near the top of MyDrHank's GLP-1 page. Two of them:
8.3% Average weight loss (semaglutide)
14.9% Average weight loss (tirzepatide)
Both carry the marker for footnote 1. Here is footnote 1, on the same page:
"Semaglutide: ~15% mean body-weight loss — STEP 1 trial… Tirzepatide: ~20.9% mean body-weight loss — SURMOUNT-1 trial…"
Neither card matches the citation attached to it.
Not one of them. On the same screen.
Where 14.9% comes from
It isn't invented. STEP 1 randomized 1,961 adults to semaglutide 2.4 mg weekly for 68 weeks and reported a mean reduction of about 15%. 1
That is semaglutide's number. It is printed on the card marked tirzepatide.
The drug is wrong, not the number.
SURMOUNT-1 — the trial MyDrHank's own footnote names for tirzepatide — randomized 2,539 adults and reported roughly 21% at the top dose over 72 weeks. 2
The correct version exists
Behind the scenes, the site holds the four-card block twice, in two versions built for the same spot:
| Weight-loss figure | semaglutide | tirzepatide |
|---|---|---|
| The block this page shows | 8.3% | 14.9% |
| The block sitting unused beside it | 15% | 20.9% |
The second row matches footnote 1 exactly. The headline sentence differs the same way — the version on this page reads "lose up to 14.9%", the unused one reads "up to 20.9%".
So this is not a seller that misunderstands the evidence. It wrote the evidence down correctly. It shipped the other draft.
Which direction the error runs
Worth saying plainly, because it cuts against the usual pattern here: this understates tirzepatide. Most claims we grade inflate a result. Nobody reading MyDrHank's page is being sold a bigger number than the trial supports.
The damage is different. When two figures on one screen disagree about the same trial, the screen stops being able to tell you anything — and the reader has no way to know that the small print is the careful half.
What the footnote gets right
Credit where it is due. Very little of this market writes a sentence like this one:
"Trial data reflects FDA-approved formulations, not the compounded versions dispensed by MyDrHank."
That is the single most important caveat in compounded GLP-1 marketing, and most sellers omit it. STEP 1 and SURMOUNT-1 tested the manufacturers' approved medicines. A compounded preparation has not been compared against them in any trial.
What it won't tell you
No pharmacy is named. "Licensed U.S. pharmacies" is as specific as it gets. No clinician is named either. No company appears in the terms.
And there is a pricing version of the same carelessness. Two of the three plan cards quote a monthly price that appears in no rung of the site's own price list — the tirzepatide card advertises $200 a month, and no rung is that.
Questions
Frequently asked questions
Is 14.9% the right number for tirzepatide?
No. It is semaglutide's result from STEP 1, and MyDrHank's own footnote says so — it cites about 20.9% for tirzepatide from SURMOUNT-1 and about 15% for semaglutide from STEP 1. The card and the citation beneath it disagree.
Where does 8.3% come from?
The page does not say, and it matches no study the page cites. What is checkable is that the card carries footnote marker one, and footnote one gives about 15% for semaglutide. A corrected version of the same card, which the site carries but does not display, reads 15%.
Is MyDrHank exaggerating?
Not in this instance, which is unusual for this market. Both figures are lower than the trials its footnote cites, so the error runs against the seller's interest. It is an accuracy problem rather than a sales tactic — but it still leaves a page that cannot settle what either drug does.
Do those trials apply to what MyDrHank sells?
Only partly, and MyDrHank says so itself — its footnote states that the trial data reflects FDA-approved formulations rather than the compounded versions it dispenses. That sentence is more honest than most of this market manages, and it means the figures describe the molecule rather than the preparation you would receive.
Which pharmacy makes the medication?
MyDrHank doesn't say. The strongest statement on the site is that medication ships from licensed, accredited U.S. pharmacies, with no facility, address or license number attached. No clinician and no operating company is named either.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021, reporting a mean reduction of about 15%.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022, reporting roughly 21% at the top dose.
- 503A
- A pharmacy that makes a drug to order for one named patient with a prescription. What it produces is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality.
Compare
Others selling what MyDrHank sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists MyDrHank is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off MyDrHank's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 21% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.